| Project/Area Number |
08670875
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
HORIBE Keizo Nagoya University, Department of Pediatrics, Associate Professor, 医学部, 助教授 (30209308)
|
|---|
| Project Period (FY) |
1996 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1998: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1997: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1996: ¥700,000 (Direct Cost: ¥700,000)
|
|---|
| Keywords | Acute lymphoblastic leukemia / Minimal residual disease / Polymerase chain reaction / Immunoglobulin heavy chain / TEL-AML1 / BCR-ABL / E2A-PBX1 / Prognostic factor / CDRIII / t(12;21) / t(1;19) / t(9;22) |
|---|
| Research Abstract |
Detection and clinical assessment of minimal residual disease (MRD) of acute lymphoblastic leukemia (ALL) were performed for 50 children with ALL diagnosed and treated between 1987 to 1997 in Nagoya University Hospital and its affiliated hospitals. E2A-PBX1, BCR-ABL and TEL-AML1 were detected by reverse transcription polymerase chain reaction (RT-PCR) method for leukemia with t (l ; 19), t (9 ; 22) or t (12 ; 21). In 26 cases of leukemia without detectable specific traslocation MRD was assessed by PCR using unique sequence of complementality determining region III of immunoglobulin heavy chain (IgH CDR III).
Bone marrow samples at 1 to 3 months after starting chemotherapy were available in 19 patients with specific fusion gene. Two of 16 patients negative for the MRD at that time relapsed later, while all the 3 patients positive for the MRD at that time relapsed later. Bone marrow samples at 1 to 3 months after starting chemotherapy were analyzed in 23 patients using specific probe for IgH CDR III.Five of 19 patients negative for the MRD at that time relapsed later, while all the 3 patients positive for the MRD at that time relapsed later. Combining these data, prognosis for patients with positive MRD at 1 to 3 months after starting chemotherapy was significantly worse than that for patients with negative MRD at that time.
Now we are going to collect the cases with uniform chemotherapy to analyze the MRD and to establish its usefulness for stratifying the treatment for childhood ALL in Japan.
|
